Stock listing

NASDAQ:MPLT MapLight Therapeutics, Inc. Stock

Home listing (NASDAQ) of MapLight Therapeutics, Inc.

Follow MapLight Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:MPLT

$5.94 USD -0.71 (-10.7%)

Close on Nov 20, 2026

Past year -55.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$5.93 – $6.48 USDNov 20, 2026
Volume
357,935 sharesNov 20, 2026
Market cap
$313.9M USDAt the close on Nov 20, 2026 · price × 52.85M shares outstanding
52-week range
$5.93 – $40.43 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$4.67M USDMedian day 411,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
MapLight Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:MPLT · Home$5.94 USD-0.71 (-10.7%)357,935$6.33$6.48$5.93$6.65Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MPLT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$5.94-0.71-10.7%$6.33$6.48$5.93357,935
$6.65+0.08+1.2%$6.50$6.86$6.43416,883
$6.57-0.33-4.8%$6.87$6.91$6.42547,765
$6.90-0.35-4.8%$7.33$7.48$6.88305,244
$7.25+0.18+2.5%$7.10$7.376$6.95367,746
$7.07-0.41-5.5%$7.46$7.635$7.01266,219
$7.48+0.04+0.5%$7.48$7.80$7.41291,886
$7.44+0.16+2.2%$7.25$7.68$7.23460,517
$7.28+0.35+5.1%$7.11$7.62$6.86458,792
$6.93+0.71+11.4%$6.24$6.93$6.06492,056
$6.22-0.49-7.3%$6.67$6.71$6.20442,663
$6.71-0.10-1.5%$6.80$7.14$6.50388,883
$6.81+0.03+0.4%$6.82$7.15$6.80345,175
$6.78-0.80-10.6%$7.65$7.665$6.765245,490
$7.58-0.14-1.8%$7.70$7.81$7.44394,984
$7.72-0.26-3.3%$8.08$8.192$7.65156,676
$7.98-0.19-2.3%$8.09$8.135$7.81365,932
$8.17+0.51+6.7%$7.66$8.25$7.50384,829
$7.66-0.31-3.9%$7.98$8.34$7.58252,481
$7.97-0.28-3.4%$8.18$8.285$7.84305,300
$8.25+0.09+1.1%$8.16$8.485$7.96349,500
$8.16-0.08-1.0%$8.21$8.58$7.995343,800
$8.24+0.24+3.0%$8.33$8.55$8.03355,000
$8.00+0.30+3.9%$7.73$8.07$7.66278,700
$7.70-0.32-4.0%$8.10$8.10$7.56359,100
$8.02+0.21+2.7%$7.84$8.43$7.743658,400
$7.81-0.065-0.8%$7.78$8.075$7.46450,900
$7.875-0.725-8.4%$8.60$8.60$7.85301,700
$8.60-0.23-2.6%$8.82$8.90$8.48485,200
$8.83-0.32-3.5%$9.15$9.415$8.70495,400
$9.15-0.21-2.2%$9.30$9.33$9.00217,600
$9.36-0.33-3.4%$9.62$9.88$9.30275,200
$9.69+0.415+4.5%$9.24$9.97$8.92495,600
$9.275-0.545-5.5%$9.80$9.80$9.19262,000
$9.82+0.19+2.0%$9.70$10.17$9.43565,700
$9.63-0.56-5.5%$10.16$10.17$9.57432,200
$10.19+0.04+0.4%$10.45$10.51$9.93303,300
$10.15-0.30-2.9%$10.64$10.64$10.12408,300
$10.45-0.01-0.1%$10.39$10.59$10.15251,600
$10.46-0.30-2.8%$10.81$10.87$10.39317,500
$10.76-0.01-0.1%$10.60$10.86$10.16341,800
$10.77-0.09-0.8%$10.89$10.93$10.13539,000
$10.86-0.04-0.4%$11.02$11.28$10.64411,300
$10.90-0.02-0.2%$11.06$11.28$10.78542,900
$10.92-0.40-3.5%$11.21$11.21$10.511,832,900
$11.32-0.08-0.7%$11.57$11.73$11.13545,900
$11.40-0.68-5.6%$12.06$12.16$11.35613,900
$12.08-1.07-8.1%$13.10$13.11$12.05402,300
$13.15+0.15+1.2%$13.08$13.45$12.66327,600
$13.00-0.785-5.7%$13.88$14.14$12.80340,200
$13.79+0.075+0.5%$13.49$14.04$13.19490,300
$13.71-0.24-1.7%$13.95$14.22$13.51500,200
$13.95+0.18+1.3%$13.49$14.09$13.19522,000
$13.77+0.63+4.8%$13.03$14.14$13.00550,900
$13.14+0.08+0.6%$13.20$13.45$12.96863,500
$13.06-0.25-1.9%$13.33$13.94$12.82937,700
$13.31+0.34+2.6%$12.99$13.93$12.32580,700
$12.97+0.37+2.9%$12.59$13.07$12.12440,600
$12.60+0.06+0.5%$12.65$12.84$12.20375,100
$12.54-0.32-2.5%$12.87$13.24$12.50741,500
$12.86+0.32+2.6%$12.47$12.95$11.71910,000
$12.54+1.18+10.4%$11.47$12.74$11.35703,481
$11.36+0.15+1.3%$11.21$11.44$10.51563,455
$11.21-0.02-0.2%$11.35$11.61$11.07435,400
$11.23-0.92-7.6%$12.07$12.21$10.96555,300
Ticker
NASDAQ:MPLT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All MapLight Therapeutics, Inc. news

MapLight Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 18 in all · newest Nov 16, 2026 · oldest 2025
Decks
8 decks · latest Nov 16, 2026

Where MapLight Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:MPLT · Home listing · This pageNASDAQUnited StatesUSD
BOATS:MPLTBOATSUnited StatesUSD

Valuation

Price/book 0.7× against a median of 2.5×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$29.84M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.28

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
MapLight Therapeutics, Inc. · NASDAQ:MPLTUS$313.9MUS$29.84Mn/an/an/a0.7×n/a0.0×1.28
Lyell Immunopharma, Inc. · NASDAQ:LYELUS$339.3MUS$196.5Mn/a13,099×n/a1.8×n/a0.2×1.51
Avacta Group PLC · LSE:AVCTUS$337.8MUS$337.2Mn/a2,281×n/a68.5×n/a5.3×n/a
Inovio Pharmaceuticals, Inc. · NASDAQ:INOUS$329.7MUS$7.56Bn/a25,303×3.4×n/an/an/a0.70
Larimar Therapeutics, Inc. · NASDAQ:LRMRUS$328.6MUS$204.7Mn/an/an/a3.2×n/a0.1×1.48
CytoDyn Inc. · OTC:CYDYUS$326.4MUS$345.8Mn/an/an/an/an/an/a0.44
C4 Therapeutics, Inc. · NASDAQ:CCCCUS$325.7MUS$175.5Mn/a5.4×n/a1.4×−282.2%0.2×1.46
Laekna, Inc. · HKEX:2105US$322.8MUS$154.7Mn/a9.7×n/a1.8×−214.9%0.0×n/a
Foresee Pharmaceuticals Co., Ltd. · TPEX:6576US$319.8MUS$303.4M469×21.2×n/a8.3×4.8%0.3×n/a
GI Innovation, Inc. · KRX:358570US$317.8MUS$288.6Mn/an/an/a4.4×n/a0.0×n/a
Atea Pharmaceuticals, Inc. · NASDAQ:AVIRUS$317.6MUS$126.6Mn/an/an/a1.8×n/a0.0×0.86
Median of the othersUS$326.0MUS$246.6M469×1,151×3.4×2.5×−214.9%0.1×1.16

Forecasts

11 strong buy · 1 buy · 3 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
26.15 USD · Analysts' mean
EPS, year to Dec 2026
-4.54 · 6 analysts

Team and board

Officers

OfficerRole
Christopher KroegerChief Executive Officer, Founder, Board Member
Jonathan GillisInterim Chief Financial Officer, Chief Administrative and Accounting Officer
Kris HansonGeneral Counsel
Anatol KreitzerChief Discovery Officer
Erin Pennock FoffChief Medical Officer
James LillieChief Scientific Officer
Karl DeisserothFounder, Scientific Advisory Board
Robert MalenkaFounder, Board of Directors, Scientific Advisory Board

Board

DirectorRole
Christopher KroegerChief Executive Officer, Founder, Board Member
George PavlovBoard Member
Maria WalkerChair of the Audit Committee
Martin BablerMember of the Audit Committee
Nanna LüneborgGeneral Partner at Forbion, Board Member
Robert MalenkaFounder, Board of Directors, Scientific Advisory Board
Tim GarnettChair of the Compensation Committee
Troy CoxChair of the Nominating and Corporate Governance Committee

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · Before open−4.8%
Q2 2026Aug 13, 2026 · After close+1.5%
Q1 2026May 15, 2026−9.5%
Q4 2025Mar 26, 2026 · Before open+6.0%
Q3 2025Dec 4, 2025 · Before open+8.4%
Q2 2025Sep 19, 2025

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck28 slidesNov 16, 2026
Investor Presentation (August 2026)Investor deck28 slidesAug 13, 2026
Technical Presentation (July 2026)Technical27 slidesJul 27, 2026
Technical Presentation (June 2026)Technical21 slidesJun 22, 2026
Investor Presentation (May 2026)Investor deck34 slidesMay 14, 2026
Investor Presentation (March 2026)Investor deck34 slidesMar 26, 2026
Investor Presentation (January 2026)Investor deck34 slidesJan 9, 2026
Investor Presentation (December 2025)Investor deck32 slidesDec 4, 2025

Open Decks

Financings

RaiseDate
Private placement of common stock and pre-funded warrants
Announced: about US$150M · US$11.38 a share · Morgan Stanley +3
Dealers: Morgan Stanley, Jefferies, Leerink Partners, Stifel
Use of proceeds: Advance ML-007C-MA, including the VISTA Phase 2 and ZEPHYR-2 Phase 3 studies, plus working capital and general corporate purposes
Aug 13, 2026
Public offering of common stock
Closed: US$17 a share · Morgan Stanley +3
Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Leerink Partners (co-lead), Stifel (co-lead)
Oct 29, 2025
Private placement of common stock
Closed: US$17 a share
Buyers: Affiliates of Goldman Sachs & Co. LLC (476,707 shares of common stock, including certain investment funds managed by Goldman Sachs & Co. LLC)
Oct 29, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$17.00 a share on Oct 26, 2025.

Price
US$17.00 a share
Shares offered
14,750,000 shares of common stock
Offering size
US$250.8 million
Underwriters' option
Up to 2,212,500 more shares
Listing
MPLT on the Nasdaq Global Select Market
Underwriters
MORGAN STANLEY, JEFFERIES, LEERINK PARTNERS, STIFEL · In the order on the cover
Shares delivered
On or about Oct 28, 2025

Steps

StepWhen
Draft sent to the SEC in confidenceMar 8, 2024
Filed publiclySep 19, 2025
Amended onceOct 6, 2025
Shares registered with an exchangeOct 24, 2025
Final prospectus, with the priceOct 27, 2025

Open IPO · From the cover of the final prospectus (424B3) filed Oct 27, 2025

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue0
Cost of revenue578.0K701.0K556.0K574.0K
Gross profit-578.0K-701.0K-556.0K-574.0K
Research and development138.3M68.5M49.1M26.6M
Selling, general and administrative30.7M14.4M7.61M4.10M
Operating income-169.1M-82.9M-57.3M-31.2M
Depreciation and amortization578.0K701.0K556.0K574.0K
EBITDA-168.5M-82.2M-56.7M-30.7M
Income before tax-161.2M-77.6M-55.7M-30.0M
Net income-161.2M-77.6M-55.7M-30.0M
Earnings per share, basic-18.56-105.38-1.34-0.72
Earnings per share, diluted-18.56-105.38

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents46.7M38.3M79.8M27.7M
Short-term investments258.4M70.5M
Current assets324.7M114.6M83.6M32.0M
Property, plant and equipment1.09M1.21M
Total assets479.5M136.9M91.4M39.4M
Accounts payable3.29M1.91M3.25M3.60M
Current liabilities16.2M15.9M14.7M12.6M
Total debt5.80M6.58M5.92M6.27M
Total liabilities21.1M21.7M20.1M18.5M
Shareholders' equity458.4M-193.6M71.3M20.9M
Shares outstanding44.0M761.3K41.4M41.4M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-138.1M-78.8M-52.0M-26.6M
Capital spending-473.0K-770.0K-462.0K-746.0K
Free cash flow-138.6M-79.6M-52.5M-27.3M
Cash from investing-323.2M-80.8M-462.0K-746.0K
Cash from financing469.8M118.1M104.6M33.2M
Change in cash8.48M-41.5M52.1M27.7M

Open Financials

Filings

FilingDateTypeFiled with
EFFECT · Notice that a registration is effectiveNov 18, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 16, 2026Material contractSEC
S-3 · Registration statementNov 16, 2026Offer documentSEC
POS AM · Amendment to an effective registrationNov 16, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportNov 16, 2026ResultsSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
144 · Notice of proposed saleOct 15, 2026Other filingsSEC
144 · Notice of proposed saleOct 15, 2026Other filingsSEC
144 · Notice of proposed saleOct 15, 2026Other filingsSEC
144 · Notice of proposed saleOct 15, 2026Other filingsSEC
144 · Notice of proposed saleOct 15, 2026Other filingsSEC
144 · Notice of proposed saleOct 15, 2026Other filingsSEC
144 · Notice of proposed saleOct 15, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveSep 24, 2026Other filingsSEC
424B3 · ProspectusSep 23, 2026Offer documentSEC
S-1/A · Registration statement, amendedSep 18, 2026Offer documentSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
144 · Notice of proposed saleSep 16, 2026Other filingsSEC
S-1 · Registration statementSep 9, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeAug 20, 2026Big-stake noticeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 18, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 3, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 31, 2026Big-stake noticeSEC
144 · Notice of proposed saleJul 30, 2026Other filingsSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 28, 2026Insider tradeSEC
8-K · Current reportJul 27, 2026Current reportSEC
4 · Change in ownershipJul 20, 2026Insider tradeSEC
4 · Change in ownershipJul 20, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
144 · Notice of proposed saleJul 17, 2026Other filingsSEC
144 · Notice of proposed saleJul 17, 2026Other filingsSEC
144/A · Notice of proposed sale, amendedJul 15, 2026Other filingsSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 25, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 25, 2026Insider tradeSEC
8-K · Current reportJun 24, 2026Meeting outcomeSEC
8-K · Current reportJun 22, 2026Current reportSEC
8-K · Current reportJun 18, 2026Management or board changeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
4 · Change in ownershipApr 29, 2026Insider tradeSEC
4 · Change in ownershipApr 29, 2026Insider tradeSEC
8-K · Current reportApr 29, 2026Management or board changeSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
144 · Notice of proposed saleApr 27, 2026Other filingsSEC
144 · Notice of proposed saleApr 27, 2026Other filingsSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
144/A · Notice of proposed sale, amendedApr 15, 2026Other filingsSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
144/A · Notice of proposed sale, amendedApr 15, 2026Other filingsSEC
144/A · Notice of proposed sale, amendedApr 15, 2026Other filingsSEC
144/A · Notice of proposed sale, amendedApr 15, 2026Other filingsSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
S-8 · Registration statement for employee plansMar 26, 2026Offer documentSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
8-K · Current reportMar 26, 2026ResultsSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 24, 2026Other filingsSEC
144 · Notice of proposed saleFeb 23, 2026Other filingsSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 20, 2026Other filingsSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
144 · Notice of proposed saleFeb 13, 2026Other filingsSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 11, 2026Other filingsSEC
144 · Notice of proposed saleFeb 10, 2026Other filingsSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 3, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
144 · Notice of proposed saleJan 30, 2026Other filingsSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
4 · Change in ownershipJan 29, 2026Insider tradeSEC
144 · Notice of proposed saleJan 29, 2026Other filingsSEC
144 · Notice of proposed saleJan 28, 2026Other filingsSEC
8-K · Current reportJan 9, 2026ResultsSEC
10-Q · Quarterly reportDec 4, 2025Quarterly reportSEC
8-K · Current reportDec 4, 2025ResultsSEC
SCHEDULE 13D · Big-stake noticeNov 20, 2025Big-stake noticeSEC
3/A · Initial statement of ownership, amendedNov 18, 2025Insider tradeSEC
SCHEDULE 13D · Big-stake noticeNov 4, 2025Big-stake noticeSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
4 · Change in ownershipOct 29, 2025Insider tradeSEC
8-K · Current reportOct 29, 2025FinancingSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
4 · Change in ownershipOct 28, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 27, 2025Insider tradeSEC
424B3 · ProspectusOct 27, 2025Offer documentSEC
S-8 · Registration statement for employee plansOct 27, 2025Offer documentSEC
FWP · Free writing prospectusOct 27, 2025Offer documentSEC
CERT · Exchange's certificate of listingOct 24, 2025Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeOct 24, 2025Other filingsSEC
FWP · Free writing prospectusOct 6, 2025Offer documentSEC
S-1/A · Registration statement, amendedOct 6, 2025Offer documentSEC
S-1 · Registration statementSep 19, 2025Offer documentSEC
DRSLTR · Letter to the SEC with a draftAug 22, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedAug 22, 2025Offer documentSEC

This page holds 200 of 217 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from MapLight Therapeutics, Inc.’s releases · as of Aug 13, 2026

Common shares
52,848,208
Fully diluted
52,848,208

Fully diluted

LineShares
Common shares52,848,208

Share count over time

CountShares
Nov 22, 202652,848,208

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Fcpm III Services B.V.4.43M10.4%US$45.1MSep 30, 2026
Goldman Sachs3.6M8.5%US$36.7MSep 30, 2026
Nan Fung Group Holdings Ltd2.3M5.4%US$23.4MSep 30, 2026
Novo Holdings A/S2.09M4.9%US$21.3MSep 30, 2026
T. Rowe Price2.08M4.9%US$21.2MSep 30, 2026
BlackRock1.71M4.0%US$17.5MSep 30, 2026
Fidelity1.54M3.6%US$15.7MSep 30, 2026
Deep Track Capital, LP1.32M3.1%US$13.4MSep 30, 2026
Baker Bros. Advisors LP1.17M2.7%US$11.9MSep 30, 2026
Sanofi912K2.1%US$9.29MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
5AM Venture Management, LLC742K1.7%US$7.56MSep 30, 2026
ADAR1 Capital Management, LLC725K1.7%US$7.39MSep 30, 2026
Vanguard641K1.5%US$6.53MSep 30, 2026
Velan Capital Investment Management LP625K1.5%US$6.37MSep 30, 2026
Marshall Wace, LLP612K1.4%US$6.24MSep 30, 2026
Pivotal bioVenture Partners Investment Advisor LLC611K1.4%US$6.23MSep 30, 2026
Blue Owl Capital Holdings LP556K1.3%US$5.67MSep 30, 2026
Two Sigma516K1.2%US$5.26MSep 30, 2026
Geode Capital441K1.0%US$4.49MSep 30, 2026
Point72 Asset Management, L.P.426K1.0%US$4.34MSep 30, 2026
Millennium424K1.00%US$4.32MSep 30, 2026
BNP Paribas416K0.98%US$4.24MSep 30, 2026
Capital Group416K0.98%US$4.24MSep 30, 2026
Trexquant Investment LP364K0.86%US$3.71MSep 30, 2026
State Street314K0.74%US$3.2MSep 30, 2026
Lazard Asset Management LLC264K0.62%US$2.69MSep 30, 2026
DAFNA Capital Management LLC156K0.37%US$1.59MSep 30, 2026
TD141K0.33%US$1.43MSep 30, 2026
Northern Trust129K0.30%US$1.32MSep 30, 2026
Schwab122K0.29%US$1.25MSep 30, 2026
Superstring Capital Management LP118K0.28%US$1.21MSep 30, 2026
UBS102K0.24%US$1.04MSep 30, 2026
Barclays85,8130.20%US$874KSep 30, 2026
Citadel85,4750.20%US$871KSep 30, 2026
Hrt Financial LP83,7370.20%US$853KSep 30, 2026
Manufacturers Life Insurance Company, The83,2740.20%US$849KSep 30, 2026
Quadrature Capital Ltd74,4850.18%US$759KSep 30, 2026
XTX Topco Ltd63,3960.15%US$646KSep 30, 2026
Morgan Stanley60,7160.14%US$619KSep 30, 2026
Citigroup Inc59,1730.14%US$603KSep 30, 2026
Jump Financial, LLC58,4610.14%US$596KSep 30, 2026
Schonfeld Strategic Advisors LLC54,0160.13%US$550KSep 30, 2026
Nuveen30,9570.07%US$315KSep 30, 2026
BNY30,2180.07%US$308KSep 30, 2026
D. E. Shaw & Co., Inc.29,3690.07%US$299KSep 30, 2026
Gsa Capital Partners LLP29,1930.07%US$297KSep 30, 2026
HSBC27,9370.07%US$284KSep 30, 2026
Ghisallo Capital Management LLC20,0000.05%US$204KSep 30, 2026
Engineers Gate Manager LP18,9520.04%US$193KSep 30, 2026
Axq Capital, LP18,9280.04%US$193KSep 30, 2026

This page holds 50 of 92 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
T. Rowe Price Small-Cap Stock Fund, Inc.625K1.5%US$22.4MJun 30, 2026
T. Rowe Price Small-Cap Value Fund, Inc.606K1.4%US$21.7MJun 30, 2026
Vanguard Total Stock Market Index Fund552K1.3%US$19.8MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF498K1.2%US$17.9MJun 30, 2026
Fidelity Stock Selector Small Cap Fund406K0.96%US$5.29MJul 31, 2026
SMALLCAP World Fund Inc404K0.95%US$14.5MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund403K0.95%US$14.4MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.399K0.94%US$14.3MJun 30, 2026
T. Rowe Price Institutional Small-Cap Stock Fund342K0.81%US$12.3MJun 30, 2026
iShares Russell 2000 ETF268K0.63%US$9.6MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Series Small Cap Opportunities Fund264K0.62%US$3.43MJul 31, 2026
Vanguard Extended Market Index Fund216K0.51%US$7.75MJun 30, 2026
Fidelity Advisor Biotechnology Fund203K0.48%US$2.64MJul 31, 2026
Fidelity Series Small Cap Core Fund138K0.33%US$1.8MJul 31, 2026
Vanguard Explorer Fund131K0.31%US$1.71MJul 31, 2026
Fidelity Small Cap Index Fund114K0.27%US$1.49MJul 31, 2026
Fidelity Extended Market Index Fund104K0.24%US$3.03MMay 31, 2026
Vanguard Russell 2000 Index Fund99,3840.23%US$2.91MMay 31, 2026
Schwab U.S. Small-Cap ETF94,6980.22%US$2.78MMay 31, 2026
iShares Russell 2000 Growth ETF83,8190.20%US$3MJun 30, 2026
T. Rowe Price Small-Mid Cap ETF63,5110.15%US$2.28MJun 30, 2026
BlackRock Health Sciences Opportunities Portfolio50,2570.12%US$1.47MMay 29, 2026
T.Rowe Price Small Cap Growth Portfolio45,2670.11%US$1.62MJun 30, 2026
Small Cap Value Portfolio42,8580.10%US$1.54MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.42,3570.10%US$1.52MJun 30, 2026
Fidelity Total Market Index Fund39,1110.09%US$1.15MMay 31, 2026
Small-Cap Value Fund35,0000.08%US$1.25MJun 30, 2026
iShares Micro-Cap ETF34,7020.08%US$1.24MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity Fund32,6040.08%US$1.17MJun 30, 2026
Fidelity Series Total Market Index Fund30,4300.07%US$892KMay 31, 2026
Fidelity Nasdaq Composite Index Fund29,3460.07%US$860KMay 31, 2026
Transamerica T. Rowe Price Small Cap VP29,1350.07%US$1.04MJun 30, 2026
Schwab Small-Cap Index Fund25,3790.06%US$330KJul 31, 2026
T. Rowe Price Spectrum Moderate Growth Allocation Fund23,1780.05%US$679KMay 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund23,0000.05%US$674KMay 31, 2026
Master Small Cap Index Series19,4950.05%US$699KJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares16,9370.04%US$221KJul 31, 2026
Small Company Growth Portfolio15,3840.04%US$551KJun 30, 2026
Nuveen Small Cap Blend Index Fund13,8650.03%US$181KJul 31, 2026
Blackstone Alternative Multi-Strategy Fund13,1510.03%US$471KJun 30, 2026
Schwab Total Stock Market Index Fund11,8370.03%US$154KJul 31, 2026
EQ/2000 Managed Volatility Portfolio11,7600.03%US$421KJun 30, 2026
SMALLCAP World Fund11,3410.03%US$406KJun 30, 2026
iShares Russell 2000 Value ETF11,2240.03%US$402KJun 30, 2026
Virtus Biotech Clinical Trials Etf11,2010.03%US$146KJul 31, 2026
Schwab U.S. Broad Market ETF10,3290.02%US$303KMay 31, 2026
Fidelity ZERO Total Market Index Fund10,1570.02%US$132KJul 31, 2026
Lazard US Small Cap Equity Select Portfolio9,5910.02%US$344KJun 30, 2026
Vanguard Russell 2000 Growth Index Fund9,4860.02%US$278KMay 31, 2026
Fidelity Small Cap Growth Index Fund8,6060.02%US$308KJun 30, 2026

This page holds 50 of 137 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Kroeger Christopher A.
Director, Officer: Chief Executive Officer
Sale73,691USD 8.08US$595KOct 15, 2026
Gillis Jonathan
Officer: CAO and Interim CFO
Sale10,167USD 8.08US$82,149Oct 15, 2026
Lillie James Woodruff
Officer: Chief Scientific Officer
Sale11,513USD 8.08US$93,025Oct 15, 2026
Hanson Kristopher
Officer: General Counsel
Sale9,020USD 8.08US$72,882Oct 15, 2026
Foff Erin Pennock
Officer: Chief Medical Officer
Sale15,355USD 8.08US$124KOct 15, 2026
Kreitzer Anatol
Officer: Chief Discovery Officer
Sale12,248USD 7.84US$96,024Oct 15, 2026
Hanson Kristopher
Officer: General Counsel
Sale16,509USD 11.67US$193KSep 16, 2026
Lillie James Woodruff
Officer: Chief Scientific Officer
Sale22,082USD 12.54US$277KAug 3, 2026
Cox Troy
Director
Buy15,620USD 9.52US$149KJul 28, 2026
Gillis Jonathan
Officer: CAO and Interim CFO
Sale600USD 36.51US$21,906Jul 17, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
Gillis Jonathan
Officer: CAO and Interim CFO
Sale16,969USD 37.61US$638KJul 17, 2026
Gillis Jonathan
Officer: CAO and Interim CFO
Sale900USD 38.17US$34,353Jul 17, 2026
Kreitzer Anatol
Officer: Chief Discovery Officer
Sale2,833USD 37.05US$105KJul 17, 2026
Kreitzer Anatol
Officer: Chief Discovery Officer
Sale14,140USD 37.70US$533KJul 17, 2026
Kreitzer Anatol
Officer: Chief Discovery Officer
Sale200USD 38.39US$7,678Jul 17, 2026
Kroeger Christopher A.
Director, Officer: Chief Executive Officer
Sale16,779USD 37.90US$636KJul 17, 2026
Lillie James Woodruff
Officer: Chief Scientific Officer
Sale2,077USD 37.90US$78,718Jul 17, 2026
Hanson Kristopher
Officer: General Counsel
Sale1,130USD 37.90US$42,827Jul 17, 2026
Foff Erin Pennock
Officer: Chief Medical Officer
Sale3,656USD 37.90US$139KJul 17, 2026
Gillis Jonathan
Officer: CAO and Interim CFO
Sale6,979USD 36.66US$256KJul 16, 2026
Gillis Jonathan
Officer: CAO and Interim CFO
Sale1,476USD 37.44US$55,261Jul 16, 2026
Kreitzer Anatol
Officer: Chief Discovery Officer
Sale7,464USD 36.66US$274KJul 16, 2026
Kreitzer Anatol
Officer: Chief Discovery Officer
Sale1,592USD 37.44US$59,604Jul 16, 2026
Kroeger Christopher A.
Director, Officer: Chief Executive Officer
Sale40,899USD 36.46US$1.49MJul 16, 2026
Kroeger Christopher A.
Director, Officer: Chief Executive Officer
Sale28,091USD 37.26US$1.05MJul 16, 2026
Kroeger Christopher A.
Director, Officer: Chief Executive Officer
Sale92USD 37.96US$3,492Jul 16, 2026
Lillie James Woodruff
Officer: Chief Scientific Officer
Sale5,009USD 36.45US$183KJul 16, 2026
Lillie James Woodruff
Officer: Chief Scientific Officer
Sale3,526USD 37.26US$131KJul 16, 2026
Lillie James Woodruff
Officer: Chief Scientific Officer
Sale12USD 37.96US$456Jul 16, 2026
Hanson Kristopher
Officer: General Counsel
Sale4,776USD 36.45US$174KJul 16, 2026
Hanson Kristopher
Officer: General Counsel
Sale3,331USD 37.26US$124KJul 16, 2026
Hanson Kristopher
Officer: General Counsel
Sale11USD 37.96US$418Jul 16, 2026
Foff Erin Pennock
Officer: Chief Medical Officer
Sale9,163USD 36.46US$334KJul 16, 2026
Foff Erin Pennock
Officer: Chief Medical Officer
Sale5,865USD 37.26US$219KJul 16, 2026
Foff Erin Pennock
Officer: Chief Medical Officer
Sale19USD 37.96US$721Jul 16, 2026
Gillis Jonathan
Officer: CAO and Interim CFO
Sale5,356USD 36.13US$194KJul 15, 2026
Gillis Jonathan
Officer: CAO and Interim CFO
Sale4,699USD 36.94US$174KJul 15, 2026
Kreitzer Anatol
Officer: Chief Discovery Officer
Sale5,545USD 36.13US$200KJul 15, 2026
Kreitzer Anatol
Officer: Chief Discovery Officer
Sale4,510USD 36.94US$167KJul 15, 2026
Kroeger Christopher A.
Director, Officer: Chief Executive Officer
Sale18,950USD 36.00US$682KJul 15, 2026
Kroeger Christopher A.
Director, Officer: Chief Executive Officer
Sale42,738USD 36.99US$1.58MJul 15, 2026
Kroeger Christopher A.
Director, Officer: Chief Executive Officer
Sale90USD 37.54US$3,379Jul 15, 2026
Lillie James Woodruff
Officer: Chief Scientific Officer
Sale2,238USD 36.00US$80,568Jul 15, 2026
Lillie James Woodruff
Officer: Chief Scientific Officer
Sale5,393USD 36.99US$199KJul 15, 2026
Lillie James Woodruff
Officer: Chief Scientific Officer
Sale12USD 37.54US$450Jul 15, 2026
Hanson Kristopher
Officer: General Counsel
Sale2,147USD 36.00US$77,292Jul 15, 2026
Hanson Kristopher
Officer: General Counsel
Sale5,103USD 36.99US$189KJul 15, 2026
Hanson Kristopher
Officer: General Counsel
Sale10USD 37.54US$375Jul 15, 2026
Foff Erin Pennock
Officer: Chief Medical Officer
Sale7,155USD 36.16US$259KJul 15, 2026
Foff Erin Pennock
Officer: Chief Medical Officer
Sale7,845USD 37.04US$291KJul 15, 2026

This page holds 50 of 133 trades. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Catalyst4, Inc.49.90%27.5MAug 14, 2026Schedule 13D
Forbion Growth Opportunities Fund III Cooperatief U.A.8.40%4.43MSep 30, 2026Schedule 13G
Nan Fung Group Holdings Limited5.50%2.92MAug 13, 2026Schedule 13G
Novo Holdings A/S4.90%2.09MJul 30, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Martin Babler
Other companies: Alumis Inc. (President, CEO and Chairman, Director · Since at least Jun 27, 2024); 89bio Inc (Director · Since at least Apr 13, 2024); Prelude Therapeutics Incorporated (Director · Since at least Jun 17, 2022); Neurogene Inc. (Director · May 12, 2022 – Jun 8, 2023 · Past)
Member of the Audit Committee · Since at least Jun 23, 2026
Troy Cox
Other companies: Standard BioTools Inc. (Director · Since at least Jun 18, 2026); Sophia Genetics SA (Board Member and Lead Independent Director · Since at least Jun 10, 2026)
Chair of the Nominating and Corporate Governance Committee · Since at least Jun 23, 2026
Kristopher Hanson
Other companies: PhaseBio Pharmaceuticals Inc (SVP and General Counsel · Nov 20, 2020 – May 20, 2022 · Past)
General Counsel · Since at least Oct 25, 2025
Maria Walker
Other companies: Five9, Inc. (Director · Since at least May 20, 2026)
Director · Since at least Jun 23, 2026
Anatol KreitzerChief Discovery Officer · Since at least Oct 16, 2026
Christopher KroegerChief Executive Officer, Director · Since at least Apr 15, 2026
Erin Pennock FoffChief Medical Officer · Since at least Apr 15, 2026
George PavlovBoard Member · Since at least Jun 25, 2026
James D TrenkleDirector · Since at least Oct 25, 2025
James LillieChief Scientific Officer · Since at least Oct 25, 2025
All 17 people
PersonSeat
Jonathan GillisInterim Chief Financial Officer, Chief Administrative and Accounting Officer · Since at least Oct 16, 2026
Karl DeisserothFounder, Scientific Advisory Board · Since at least Oct 6, 2026
Kris HansonGeneral Counsel · Since at least Oct 16, 2026
Nanna LüneborgDirector · Since at least Jun 23, 2026
Robert MalenkaFounder, Board of Directors, Scientific Advisory Board · Since at least Apr 17, 2026
Timothy GarnettDirector · Since at least Oct 25, 2025
Vishwas SetiaChief Financial Officer · Since at least Oct 25, 2025

Open People

Log in to ask 6ix AI your own questions about MapLight Therapeutics, Inc.